Vanda Pharmaceuticals (VNDA) Current Assets (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Current Assets data on file, last reported at $293.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 28.13% year-over-year to $293.2 million; the trailing twelve-month figure through Mar 2026 stood at $293.2 million (down 28.13% YoY), and the FY2025 full-year result was $347.3 million, down 20.88% from the prior year.
• Current Assets retreated to $293.2 million in Q1 2026, from $347.3 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $536.6 million in Q3 2023 to a low of $293.2 million in Q1 2026.
• A 5-year average of $447.8 million and a median of $439.2 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets advanced 16.87% in 2022 and fell 28.13% in 2026, its largest moves.
• Tracing VNDA's Current Assets over 5 years: stood at $519.3 million in 2022, then dropped by 16.63% to $432.9 million in 2023, then climbed by 1.37% to $438.9 million in 2024, then dropped by 20.88% to $347.3 million in 2025, then fell by 15.58% to $293.2 million in 2026.
• Business Quant data shows VNDA's Current Assets at $293.2 million in Q1 2026, $347.3 million in Q4 2025, and $367.5 million in Q3 2025.